BackMineralys Therapeutics Overview

Mineralys Therapeutics Long Term Debt

Mineralys Therapeutics's long-term debt is $98M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$97.62M

Peer trimmed avg / median

Loading

Mineralys Therapeutics Long Term Debt History

Loading

Mineralys Therapeutics vs. peers: Long Term Debt Comparison

Loading

Mineralys Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Mineralys Therapeutics (MLYS) FAQ

Mineralys Therapeutics (MLYS) currently reports a long-term debt of $98M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Mineralys Therapeutics's long-term debt history and peer comparisons.

Mineralys Therapeutics's long-term debt changed from $0 to $98M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mineralys Therapeutics reported $98M in long-term debt as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $98M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Mineralys Therapeutics, and consider following MLYS for alerts when major investors trade the stock.